How the face and body change in the first year of Gender-Affirming Hormone Therapy in the public health system

Facial and body morphological changes during the first year of Gender-Affirming Hormone Therapy in the brazilian public health system - SUS Unified Health System

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

REBEC

Registry ID

RBR-99w496d

Enrollment

Registered

2026-07-16

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transgender Persons Anthropometry

Interventions

Observational, analytical, longitudinal, and prospective clinical cohort study with repeated measures and comparison between two parallel groups composed of transgender women (n˜48) and transgender me

Eligibility

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Individuals aged between 18 and 50 years; transgender persons classified according to gender identity as transgender men or transgender women; in the initial phase of gender-affirming hormone therapy according to the standardized clinical protocol of the Brazilian Public Health System; transgender men receiving testosterone; transgender women receiving estrogen, either alone or in combination with cyproterone or spironolactone, according to individual clinical indication

Exclusion criteria

Exclusion criteria: Refusal to sign the informed consent form; cognitive impairment preventing adequate understanding of the study procedures; use of analgesics, nonsteroidal anti-inflammatory drugs, or opioids within 24 hours prior to assessments; history of craniofacial trauma; previous facial plastic surgery; history of facial aesthetic procedures; active orthodontic treatment; extensive oral rehabilitation with potential impact on facial morphology; pregnancy; presence of pacemakers, implantable defibrillators, or other internal electronic devices

Design outcomes

Primary

Measure	Time frame
To evaluate changes in total facial volume (cm³) during the first year of gender-affirming hormone therapy. Differences in facial morphology over time are expected, with the main comparison between baseline and 12 months. Outcome assessment will be performed using three-dimensional structured-light facial scanning, with digital model generation and volumetric difference calculations across time points (baseline, 3, 6, and 12 months).	—

Measure

Time frame

To evaluate changes in total facial volume (cm³) during the first year of gender-affirming hormone therapy. Differences in facial morphology over time are expected, with the main comparison between baseline and 12 months. Outcome assessment will be performed using three-dimensional structured-light facial scanning, with digital model generation and volumetric difference calculations across time points (baseline, 3, 6, and 12 months).

—

Secondary

Measure	Time frame
To evaluate regional facial, skeletal, and body morphological changes during the first year of gender-affirming hormone therapy. Changes in the volumetric distribution of facial soft tissues (mandible, maxilla, chin, forehead, and lips), maxillary and mandibular bone structures, and body composition parameters over time are expected, as well as differences in the magnitude and temporal pattern of these changes between transgender men and transgender women. Outcomes will be assessed using three-dimensional structured-light facial scanning for regional soft tissue volumetric analysis (baseline, 3, 6, and 12 months), cone-beam computed tomography for volumetric evaluation of maxillary and mandibular bone structures (baseline and 12 months), and segmental multifrequency bioelectrical impedance analysis for body composition assessment (baseline, 3, 6, and 12 months), including total body water, intracellular and extracellular water, skeletal muscle mass, lean mass, body fat mass, body fat percentage, body mass index, and basal metabolic rate.	—

Measure

Time frame

To evaluate regional facial, skeletal, and body morphological changes during the first year of gender-affirming hormone therapy. Changes in the volumetric distribution of facial soft tissues (mandible, maxilla, chin, forehead, and lips), maxillary and mandibular bone structures, and body composition parameters over time are expected, as well as differences in the magnitude and temporal pattern of these changes between transgender men and transgender women. Outcomes will be assessed using three-dimensional structured-light facial scanning for regional soft tissue volumetric analysis (baseline, 3, 6, and 12 months), cone-beam computed tomography for volumetric evaluation of maxillary and mandibular bone structures (baseline and 12 months), and segmental multifrequency bioelectrical impedance analysis for body composition assessment (baseline, 3, 6, and 12 months), including total body water, intracellular and extracellular water, skeletal muscle mass, lean mass, body fat mass, body fat percentage, body mass index, and basal metabolic rate.

—

Countries

Contacts

Public ContactPriscilla Soares

Faculdade de Odontologia - Universidade Federal de Uberlândia

pbfsoares@yahoo.com.br+55-34-99770088

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Aug 10, 2026